Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis

BACKGROUND: After the approval of pazopanib for the treatment of soft tissue sarcoma (STS), pneumothorax was reported as an unexpected adverse event during pazopanib treatment. The incidence and risk factors of pneumothorax during pazopanib treatment for STSs have not been established yet. METHODS:...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Main Authors: Nakano, Kenji, Motoi, Noriko, Tomomatsu, Junichi, Gokita, Tabu, Ae, Keisuke, Tanizawa, Taisuke, Matsumoto, Seiichi, Takahashi, Shunji
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2016
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5035441/
https://ncbi.nlm.nih.gov/pubmed/27663525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2786-z
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares